PMID- 22562364
OWN - NLM
STAT- MEDLINE
DCOM- 20120904
LR  - 20161125
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 28
IP  - 1
DP  - 2012 Jul
TI  - Expression and correlation of Bcl-2 with pathological grades in human glioma stem 
      cells.
PG  - 155-60
LID - 10.3892/or.2012.1800 [doi]
AB  - The anti-apoptotic gene, B-cell lymphoma-2 (Bcl-2), has been reported to be 
      overexpressed in gliomas and is related to tumor prognosis, suggesting a 
      potential therapeutic target. Additionally, recent studies have demonstrated the 
      existence of brain glioma stem cells (BGSCs) which are tumorigenic, 
      self-renewable and dominate the biological behavior of gliomas. Currently BGSCs 
      are committed as a new target of glioma therapies. However, few studies have 
      focused on the expression of Bcl-2 in BGSCs. We performed a series of experiments 
      to culture BGSCs from eight clinical specimens, followed by real-time RT-PCR and 
      immunoassays to compare the expression levels of Bcl-2 in BGSCs and their 
      corresponding primary glioma cells (PGCs). The results showed that Bcl-2 mRNA and 
      protein expression levels are higher in BGSCs compared to their counterparts, and 
      the expression levels are related to glioma malignancies. As an anti-apoptotic 
      gene, Bcl-2 assigns immortality characteristics to cells, which coincide with the 
      pivotal biological feature of BGSCs. The experimental results indicated that 
      BGSCs would evade apoptosis for higher Bcl-2 expression, and may interpret the 
      drug resistance of glioma to cytotoxic drugs and other pro-apoptotic agents. New 
      therapies targeting Bcl-2 must induce apoptosis in BGSCs, thus, resulting in 
      treatment or even eradication of glioma.
FAU - Qiu, Bo
AU  - Qiu B
AD  - Department of Neurosurgery, First Hospital of China Medical University, Heping 
      District, Shenyang, Liaoning 110001, PR China.
FAU - Wang, Yong
AU  - Wang Y
FAU - Tao, Jun
AU  - Tao J
FAU - Wang, Yunjie
AU  - Wang Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120504
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (AC133 Antigen)
RN  - 0 (Antigens, CD)
RN  - 0 (Glycoproteins)
RN  - 0 (Peptides)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
SB  - IM
MH  - AC133 Antigen
MH  - Antigens, CD/metabolism
MH  - Brain Neoplasms/metabolism/*pathology
MH  - Cell Proliferation
MH  - Glioma/metabolism/*pathology
MH  - Glycoproteins/metabolism
MH  - Humans
MH  - Neoplastic Stem Cells/*metabolism
MH  - Peptides/metabolism
MH  - Proto-Oncogene Proteins c-bcl-2/genetics/*metabolism
MH  - Real-Time Polymerase Chain Reaction
MH  - Spheroids, Cellular/metabolism
MH  - Transcription, Genetic
MH  - Tumor Cells, Cultured
EDAT- 2012/05/09 06:00
MHDA- 2012/09/05 06:00
CRDT- 2012/05/08 06:00
PHST- 2012/02/24 00:00 [received]
PHST- 2012/04/12 00:00 [accepted]
PHST- 2012/05/08 06:00 [entrez]
PHST- 2012/05/09 06:00 [pubmed]
PHST- 2012/09/05 06:00 [medline]
AID - 10.3892/or.2012.1800 [doi]
PST - ppublish
SO  - Oncol Rep. 2012 Jul;28(1):155-60. doi: 10.3892/or.2012.1800. Epub 2012 May 4.